Toward the detection of prostate cancer in urine: a critical analysis.
Toward the detection of prostate cancer in urine: a critical analysis.
复制标题
DOI：
10.1016/j.juro.2012.04.143
复制
发表时间：
2013-02
影响因子：
6.6
通讯作者：
Jarrard, David F.
中科院分区：
文献类型：
--
作者：
Matthew Truong;Yang, Bing;Jarrard, David F.
前列腺特异性抗原（PSA）和直肠指检（DRE）对前列腺癌（PCa）的检测特异性较低，对侵袭性疾病的预测能力较差。尿液容易获得，无创，是早期检测和预测前列腺癌预后的生物标志物的有希望的来源。本综述的目的是确定基于尿液的PCa的有前途的生物标志物，检查趋势，并概述潜在的缺陷。在Pubmed®和Web of Science®数据库中检索同行评议的PCa尿液检测文献。对这一课题的原始研究和少量综述进行了分析，包括优缺点。我们提供了基于尿液的前列腺癌检测的全面回顾，涵盖了技术方面，包括尿液收集方法，以及生物标志物在基因组学、表观遗传学、转录组学、蛋白质组学和代谢组学领域的最新发展。尿液收集的过程是可变的，这可能导致相互矛盾的临床结果。在尿液中检测PCa在技术上是可行的，正如许多“原理证明”研究所证明的那样，但很少有标记物在多个大样本集中得到验证。近年来，利用尿液开发生物标志物的研究一直在加速，许多研究鉴定了尿液中基于DNA、RNA、蛋白质和代谢物的生物标志物。先进的临床研究已经确定PCA3和TMPRSS2:ERG融合转录物是癌症检测和可能预后的有前途的RNA标记物。多基因的DNA甲基化分析提高了特异性，为临床级检测的发展提供了一个有希望的平台。基于尿液的检测是非侵入性的，代表了PCa新的生物标志物的丰富来源。尽管尿液在检测癌症方面表现出希望，但识别前列腺癌侵袭性亚群的能力需要进一步发展。
Prostate specific antigen (PSA) and digital rectal exam (DRE) have low specificity for the detection of prostate cancer (PCa) and poorly predict the presence of aggressive disease. Urine is readily available, non-invasive, and represents a promising source of biomarkers for early detection and prediction of PCa prognosis. The goal of this review is to identify promising biomarkers for urine-based PCa, examine trends, and outline potential pitfalls. Pubmed® and Web of Science® database searches of peer-reviewed literature on urine-based testing in PCa were performed. Original studies on this subject, as well as a small number of reviews, were analyzed including the strengths and weaknesses. We provide a comprehensive review of urine-based testing for PCa that covers the technical aspects including the methodology of urine collection, as well as recent developments in biomarkers spanning the fields of genomics, epigenetics, transcriptomics, proteomics, and metabolomics. The process of urine collection is subject to variability, which may result in conflicting clinical results. Detecting PCa in urine is technically feasible as demonstrated by numerous “proof-of principle” studies, but few markers have been validated in multiple large sample sets. Biomarker development using urine has been accelerating in recent years, with numerous studies identifying DNA, RNA, protein, and metabolite-based biomarkers in the urine. Advanced clinical studies have identified PCA3 and TMPRSS2:ERG fusion transcripts as promising RNA markers for cancer detection and possibly prognosis. DNA methylation analysis of multiple genes improves specificity, and represents a promising platform for the development of clinical-grade assays. Urine-based testing is non-invasive and represents a rich source of novel biomarkers for PCa. Although urine demonstrates promise in detecting cancer, the ability to identify aggressive subsets of PCa needs further development.
登录
查看更多内容
影响因子：
3.7
作者：
Cannas A;Kalunga G;Green C;Calvo L;Katemangwe P;Reither K;Perkins MD;Maboko L;Hoelscher M;Talbot EA;Mwaba P;Zumla AI;Girardi E;Huggett JF;TB trDNA consortium
通讯作者：
TB trDNA consortium
影响因子：
6.6
作者：
Nakanishi, Hiroyuki;Groskopf, Jack;Babaian, R. Joseph
通讯作者：
Babaian, R. Joseph
影响因子：
6.6
作者：
Deras, Ina L.;Aubin, Sheila M. J.;Groskopf, Jack
通讯作者：
Groskopf, Jack
影响因子：
23.4
作者：
Chun, Felix K.;de la Taille, Alexandre;Haese, Alexander
通讯作者：
Haese, Alexander
影响因子：
2.1
作者：
Marks, Leonard S.;Fradet, Yves;Groskopf, Jack
通讯作者：
Groskopf, Jack